Acceptance and commitment therapy

BioRay Filed IND Application for BRY812, a Novel Antibody Drug Conjugate Targeting LIV-1

Retrieved on: 
Wednesday, May 24, 2023

LIV-1, also known as SLC39A6 or ZIP6, is a multi-pass transmembrane protein with zinc transporter and metalloproteinase activity.

Key Points: 
  • LIV-1, also known as SLC39A6 or ZIP6, is a multi-pass transmembrane protein with zinc transporter and metalloproteinase activity.
  • BRY812 is a LIV-1 targeting ADC developed on BioRay's CysLink™ technology platform where highly stable conjugation is created through irreversible chemistry.
  • Globally, no LIV-1 targeting ADC has received marketing approval yet, and BioRay's BRY812 is anticipated to be the second LIV-1 ADC that reaches the clinical stage.
  • Dr. Haibin Wang, CEO of BioRay, stated, "Since this January, we have obtained the IND approval of two innovative antibody drug candidates, BR108 and BRY805.

BioRay Filed IND Application for BRY812, a Novel Antibody Drug Conjugate Targeting LIV-1

Retrieved on: 
Wednesday, May 24, 2023

LIV-1, also known as SLC39A6 or ZIP6, is a multi-pass transmembrane protein with zinc transporter and metalloproteinase activity.

Key Points: 
  • LIV-1, also known as SLC39A6 or ZIP6, is a multi-pass transmembrane protein with zinc transporter and metalloproteinase activity.
  • BRY812 is a LIV-1 targeting ADC developed on BioRay's CysLink™ technology platform where highly stable conjugation is created through irreversible chemistry.
  • Globally, no LIV-1 targeting ADC has received marketing approval yet, and BioRay's BRY812 is anticipated to be the second LIV-1 ADC that reaches the clinical stage.
  • Dr. Haibin Wang, CEO of BioRay, stated, "Since this January, we have obtained the IND approval of two innovative antibody drug candidates, BR108 and BRY805.

JMIR AI | MOBILE ARTIFICIAL INTELLIGENCE-POWERED ACCEPTANCE COMMITMENT THERAPY TOOL

Retrieved on: 
Tuesday, February 28, 2023

TORONTO and PHILADELPHIA, Feb. 28, 2023 /PRNewswire/ -- JMIR Publications published "Adolescents' Well-being While Using a Mobile Artificial Intelligence-Powered Acceptance Commitment Therapy Tool: Evidence From a Longitudinal Study" in their journal JMIR AI, which showed the potential for using mobile-based conversational agents to deliver engaging and effective Acceptance Commitment Therapy interventions for adolescents. Smartphone-based conversational agents can provide psychologically driven interventions and support, which can increase psychological well-being over time.

Key Points: 
  • TORONTO and PHILADELPHIA, Feb. 28, 2023 /PRNewswire/ -- JMIR Publications published "Adolescents' Well-being While Using a Mobile Artificial Intelligence-Powered Acceptance Commitment Therapy Tool: Evidence From a Longitudinal Study" in their journal JMIR AI , which showed the potential for using mobile-based conversational agents to deliver engaging and effective Acceptance Commitment Therapy interventions for adolescents.
  • The objective of the study was to test the potential of an automated conversational agent named Kai.ai to deliver a self-help program based on Acceptance Commitment Therapy tools for adolescents, aimed to increase their well-being.
  • A total of 10,387 adolescents aged 14-18 years who used Kai.ai on one of the top messaging apps participated in this study.
  • The World Health Organization Well-being Index questionnaire assessed users' well-being levels between 2 and 5 times during the study.

Luna Adolescent Services Now Accepting Clients in Houston, Texas

Retrieved on: 
Thursday, October 6, 2022

HOUSTON, Oct. 6, 2022 /PRNewswire/ --Luna Recovery Services, a first-class Substance Use Disorder and Mental Health treatment center in Houston, Texas, is proud to announce the launch of its Adolescent Intensive Outpatient Program (IOP) this month.

Key Points: 
  • HOUSTON, Oct. 6, 2022 /PRNewswire/ --Luna Recovery Services, a first-class Substance Use Disorder and Mental Health treatment center in Houston, Texas, is proud to announce the launch of its Adolescent Intensive Outpatient Program (IOP) this month.
  • "It is exciting to offer a therapeutic program for adolescents and their families," Luna's Chief Clinical Officer, Dr. John O'Neill, said.
  • Luna Recovery's new adolescent intensive outpatient program consists of:
    3 hours of group therapy 3 days a week.
  • Luna Recovery is a top-rated facility dedicated to providing a variety of high-quality treatment services to adolescents and adults struggling with substance use and mental health issues.

ieso Announces Results Showing Novel Form of Online Cognitive Behavioral Therapy Improves Patient Outcomes in Type 2 Diabetes

Retrieved on: 
Monday, June 6, 2022

This study, conducted with support from Roche Diabetes Care Limited, enrolled 102 patients and evaluated the effect of a novel online CBT tailored for patients with type 2 diabetes.

Key Points: 
  • This study, conducted with support from Roche Diabetes Care Limited, enrolled 102 patients and evaluated the effect of a novel online CBT tailored for patients with type 2 diabetes.
  • The online CBT therapy was delivered by therapists that were specially trained to understand the physical symptoms of diabetes and how to manage them.
  • Therapists were also trained to use an innovative form of cognitive behavioral therapy, Acceptance and Commitment Therapy, that allowed for a more personalized approach.
  • "Were excited to announce these results, which show that diabetes-specific online cognitive behavioral therapy can improve patient outcomes in Type 2 diabetes management and care.

D'Amore Healthcare is In-Network with United Health Group

Retrieved on: 
Wednesday, January 12, 2022

UnitedHealth Group provides several behavioral health plans through their subsidiaries including UBH (United Behavioral Health), Optum, and Oscar.

Key Points: 
  • UnitedHealth Group provides several behavioral health plans through their subsidiaries including UBH (United Behavioral Health), Optum, and Oscar.
  • UnitedHealth Group works with governments, employers, providers, and partners like D'Amore Healthcare to help insure 146 million people.
  • UnitedHealth Group has decided to partner with us to offer quality behavioral health care to its subscribers.
  • UnitedHealth Group is now included in the list of In-Network providers that are partnered with D'Amore Healthcare including Anthem BCBS, Blue Cross Blue Shield, and Health Net/MHN.

Sorrento Receives FDA Clearance to Proceed With Clinical Trial for Anti-TROP-2 Antibody Drug Conjugate (TROP-2 ADC) for multiple solid tumors

Retrieved on: 
Wednesday, October 13, 2021

ESG-401 addresses a highly unmet need for the treatment of multiple solid tumors, including triple-negative breast cancer and urothelial carcinoma.

Key Points: 
  • ESG-401 addresses a highly unmet need for the treatment of multiple solid tumors, including triple-negative breast cancer and urothelial carcinoma.
  • Today Sorrento announces that the US FDA has given clearance to proceed with clinical trials in cancer patients with relapsed or refractory solid tumors.
  • Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19.
  • RTX has completed a Phase 1B trial for intractable pain associated with cancer and a Phase 1B trial in osteoarthritis patients.